Literature DB >> 18704099

Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence.

Falk W Lohoff1, Andrew E Weller, Paul J Bloch, Aleksandra H Nall, Thomas N Ferraro, Kyle M Kampman, Helen M Pettinati, David W Oslin, Charles A Dackis, Charles P O'Brien, Wade H Berrettini.   

Abstract

Dopaminergic brain systems have been documented to have a major role in drug reward, thus making genes involved in these circuits plausible candidates for susceptibility to substance use disorders. The catechol-O-methyltransferase (COMT) is involved in the degradation of catecholamines and a functional polymorphism (Val158Met) has been suggested to influence enzyme activity. In this study we hypothesize that genetic variation in the COMT gene contributes to increased risk for cocaine dependence. Cocaine-dependent individuals (n=330) and screened unaffected normal controls (n=255) were genotyped for three SNPs in the COMT gene (rs737865, rs4680 (Val158Met), rs165599). All cases and controls were of African descent. Genotype and allele frequencies differed significantly for the Val158Met polymorphism between cases (f(Met)=35%) and controls (f(Met)=27%) (p=0.004; corrected p=0.014; OR 1.44; 95% CI 1.12-1.86). Haplotype analysis showed a significant association for a two-marker haplotype rs737865-Val158Met (p=0.005). Results suggest that variation in COMT increases risk for cocaine dependence. The low enzyme activity 158Met allele or haplotypes containing this variant might have functional effects on dopamine-derived reward processes and cortical functions resulting in increased susceptibility for cocaine dependence. Additional studies are required to elucidate the role of COMT in the pathophysiology of substance use disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704099      PMCID: PMC2583214          DOI: 10.1038/npp.2008.126

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  50 in total

1.  Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data.

Authors:  D Fallin; N J Schork
Journal:  Am J Hum Genet       Date:  2000-08-22       Impact factor: 11.025

2.  High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers.

Authors:  D J Vandenbergh; L A Rodriguez; I T Miller; G R Uhl; H M Lachman
Journal:  Am J Med Genet       Date:  1997-07-25

3.  Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles.

Authors:  M A Palmatier; A M Kang; K K Kidd
Journal:  Biol Psychiatry       Date:  1999-08-15       Impact factor: 13.382

Review 4.  The TDT and other family-based tests for linkage disequilibrium and association.

Authors:  R S Spielman; W J Ewens
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

5.  Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism.

Authors:  J Tiihonen; T Hallikainen; H Lachman; T Saito; J Volavka; J Kauhanen; J T Salonen; O P Ryynänen; M Koulu; M K Karvonen; T Pohjalainen; E Syvälahti; J Hietala
Journal:  Mol Psychiatry       Date:  1999-05       Impact factor: 15.992

6.  Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study.

Authors:  R Horowitz; M Kotler; E Shufman; S Aharoni; I Kremer; H Cohen; R P Ebstein
Journal:  Am J Med Genet       Date:  2000-10-09

7.  Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene.

Authors:  D J Vandenbergh; L A Rodriguez; E Hivert; J H Schiller; G Villareal; E W Pugh; H Lachman; G R Uhl
Journal:  Am J Med Genet       Date:  2000-10-09

8.  Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior.

Authors:  T Hallikainen; H Lachman; T Saito; J Volavka; J Kauhanen; J T Salonen; O P Ryynänen; M Koulu; M K Karvonen; T Pohjalainen; E Syvälahti; J Hietala; J Tiihonen
Journal:  Am J Med Genet       Date:  2000-06-12

9.  Association between the functional polymorphism of catechol-O-methyltransferase gene and alcohol consumption among social drinkers.

Authors:  J Kauhanen; T Hallikainen; T P Tuomainen; M Koulu; M K Karvonen; J T Salonen; J Tiihonen
Journal:  Alcohol Clin Exp Res       Date:  2000-02       Impact factor: 3.455

10.  Cocaine use, abuse and dependence in a population-based sample of female twins.

Authors:  K S Kendler; C A Prescott
Journal:  Br J Psychiatry       Date:  1998-10       Impact factor: 9.319

View more
  23 in total

1.  Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans.

Authors:  Orna Levran; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Ann Hum Genet       Date:  2015-02-27       Impact factor: 1.670

2.  Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence.

Authors:  Falk W Lohoff; Paul J Bloch; Thomas N Ferraro; Wade H Berrettini; Helen M Pettinati; Charles A Dackis; Charles P O'Brien; Kyle M Kampman; David W Oslin
Journal:  Neurosci Lett       Date:  2009-02-21       Impact factor: 3.046

3.  Catehol-o-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trial.

Authors:  Kathleen M Carroll; Aryeh Herman; Elise E DeVito; Tami L Frankforter; Marc N Potenza; Mehmet Sofuoglu
Journal:  Am J Addict       Date:  2015-05-01

Review 4.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 5.  Role of placebo effects in pain and neuropsychiatric disorders.

Authors:  Annabelle M Belcher; Sergi Ferré; Pedro E Martinez; Luana Colloca
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-06-14       Impact factor: 5.067

6.  Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs.

Authors:  Kenneth Blum; Thomas Simpatico; Marcelo Febo; Chris Rodriquez; Kristina Dushaj; Mona Li; Eric R Braverman; Zsolt Demetrovics; Marlene Oscar-Berman; Rajendra D Badgaiyan
Journal:  Mol Neurobiol       Date:  2016-05-31       Impact factor: 5.590

Review 7.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 8.  Environmental, genetic and epigenetic contributions to cocaine addiction.

Authors:  R Christopher Pierce; Bruno Fant; Sarah E Swinford-Jackson; Elizabeth A Heller; Wade H Berrettini; Mathieu E Wimmer
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

9.  Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations.

Authors:  Rungnapa Ittiwut; Jennifer B Listman; Chupong Ittiwut; Joseph F Cubells; Roger D Weiss; Kathleen Brady; David Oslin; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-06-08       Impact factor: 3.568

10.  Genetic association of GABA-A receptor alpha-2 and mu opioid receptor with cocaine cue-reactivity: evidence for inhibitory synaptic neurotransmission involvement in cocaine dependence.

Authors:  David Smelson; Lei Yu; Steven Buyske; Gerardo Gonzalez; Jay Tischfield; Curtis K Deutsch; Douglas Ziedonis
Journal:  Am J Addict       Date:  2012 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.